Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
Enzo Biochem, Inc. (OTCQX:ENZB), currently valued at $36.59 million and trading below book value, saw its shareholders approve a merger with Bethpage Parent, Inc. at a special meeting held Tuesday, according to a press release statement based on a Securities and Exchange Commission filing. InvestingPro data shows the stock has gained over 32% in the past six months.
The meeting saw participation from holders of 34,336,390 shares, representing approximately 65.58% of the company’s outstanding common stock as of the July 15 record date. Shareholders voted on the adoption of the Agreement and Plan of Merger, dated June 23, 2025, under which Bethpage Merger Sub, Inc., a wholly owned subsidiary of Bethpage Parent, will merge with and into Enzo Biochem.
The merger proposal received 29,964,566 votes in favor, 4,306,757 votes against, and 65,067 abstentions.
A second proposal, which would have allowed adjournment of the meeting to solicit additional proxies if needed, was not presented, as the merger proposal had already been approved.
The closing of the merger is expected to occur on or about Wednesday, subject to the satisfaction or waiver of remaining closing conditions specified in the merger agreement.
All information is based on a press release statement and the company’s SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.